API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-announces-first-patient-enrolled-in-limt-2-a-phase-3-study-of-peginterferon-lambda-in-patients-with-chronic-hepatitis-delta-virus-hdv-infection-301449320.html
https://www.clinicaltrialsarena.com/news/triple-drug-combo-covid-19/
https://www.clinicaltrialsarena.com/news/bausch-health-initiates-virazole-trial/
https://cen.acs.org/sections/coronavirus/biological-chemistry/infectious-disease/coronavirus-drug-repurposing.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125499
http://www.pharmatimes.com/news/abbvie_reports_99_cure_rate_for_pan-genotypic_hep_c_therapy_1191657
http://www.dddmag.com/news/2017/03/japan-grants-priority-review-abbvies-investigational-regimen-all-major-hcv-genotypes
http://www.fiercebiotech.com/biotech/aviragen-takes-a-tumble-as-rsv-drug-fails-mid-stage-trial
http://www.pharmatimes.com/news/smc_oks_four_new_therapies_for_nhs_use_in_scotland_1184395
http://www.prnewswire.com/news-releases/mylan-signs-sub-license-agreement-with-the-medicines-patent-pool-to-increase-access-to-hepatitis-c-treatment-in-developing-countries-300368162.html
http://www.drug-dev.com/Main/Back-Issues/HCV-MARKET-Recent-Success-in-HCV-Treatment-Brings-1213.aspx
http://www.prnewswire.com/news-releases/abbvie-receives-us-fda-approval-of-supplemental-new-drug-application-for-viekira-pak-ombitasvir-paritaprevir-and-ritonavir-tablets-dasabuvir-tablets-without-ribavirin-in-genotype-1b-chronic-hepatitis-c-patients-with-compen-300256641.html
http://www.pharmafile.com/news/503902/merck-says-its-zepatier-showed-better-efficacy-and-safety-compared-competition-phase-iii
http://www.fiercepharma.com/story/australia-bets-1b-pricey-hep-c-drugs-broad-effort-eradicate-disease/2015-12-23
http://in.reuters.com/article/2015/11/12/us-gilead-sciences-fda-idINKCN0T12UA20151112?rpc=401
http://www.fiercepharmaasia.com/story/abbvie-nears-launch-viekira-crowded-japan-hcv-battle/2015-11-04
http://www.pharmatimes.com/Article/15-10-06/Merck_drug_could_offer_Hep_C_cure_to_kidney_disease_patients.aspx
http://www.reuters.com/article/2015/06/24/us-abbvie-study-idUSKBN0P413320150624
http://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?action=select&recall_number=D-0379-2015&w=01282015&lang=eng
http://www.pmlive.com/pharma_news/nice_backs_new_hepatitis_c_treatments_631606
http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-north-america-llc-issues-voluntary-recall-of-virazole-ribavirin-powder-for-solution-in-the-united-states-300014681.html
http://www.fiercepharma.com/story/ca-panel-gileads-harvoni-cost-effective-95k-only-affordable-half-price/2014-12-15
http://www.Prnewswire.com/news-releases/class-action-lawsuit-challenges-the-exorbitant-pricing-of-gileads-hepatitis-c-drug-sovaldi-300007372.html